EA202190621A1 - Фармацевтическая композиция, содержащая антитромбоцитарное средство и ингибитор секреции желудочной кислоты - Google Patents

Фармацевтическая композиция, содержащая антитромбоцитарное средство и ингибитор секреции желудочной кислоты

Info

Publication number
EA202190621A1
EA202190621A1 EA202190621A EA202190621A EA202190621A1 EA 202190621 A1 EA202190621 A1 EA 202190621A1 EA 202190621 A EA202190621 A EA 202190621A EA 202190621 A EA202190621 A EA 202190621A EA 202190621 A1 EA202190621 A1 EA 202190621A1
Authority
EA
Eurasian Patent Office
Prior art keywords
pharmaceutical composition
antitlambocytic
composition containing
gastric acid
acid secretion
Prior art date
Application number
EA202190621A
Other languages
English (en)
Inventor
Тэ Кын Чо
Ён Дэ Чо
Ынчжи Квон
Мюн Чжин Син
Original Assignee
ЭйчКей ИННО.Эн КОРПОРЕЙШН
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ЭйчКей ИННО.Эн КОРПОРЕЙШН filed Critical ЭйчКей ИННО.Эн КОРПОРЕЙШН
Publication of EA202190621A1 publication Critical patent/EA202190621A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

В настоящем изобретении предложена фармацевтическая композиция, содержащая клопидогрел или его фармацевтически приемлемые соли и соединение формулы 1 или его фармацевтически приемлемые соли в качестве активного ингредиента. Полезное действие фармацевтической композиции по настоящему изобретению заключается в поддержании лечебного эффекта клопидогрела при одновременном предупреждении или лечении побочного эффекта клопидогрела, а именно расстройств желудочно-кишечного тракта.
EA202190621A 2018-08-28 2019-08-27 Фармацевтическая композиция, содержащая антитромбоцитарное средство и ингибитор секреции желудочной кислоты EA202190621A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020180101047A KR20200024413A (ko) 2018-08-28 2018-08-28 항혈소판제와 산 분비 억제제를 포함하는 약학 조성물
PCT/KR2019/010891 WO2020045940A1 (en) 2018-08-28 2019-08-27 Pharmaceutical composition comprising antiplatelet agent and gastric acid secretion inhibitor

Publications (1)

Publication Number Publication Date
EA202190621A1 true EA202190621A1 (ru) 2021-06-03

Family

ID=69644592

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202190621A EA202190621A1 (ru) 2018-08-28 2019-08-27 Фармацевтическая композиция, содержащая антитромбоцитарное средство и ингибитор секреции желудочной кислоты

Country Status (17)

Country Link
US (1) US20210251967A1 (ru)
EP (1) EP3843722A4 (ru)
JP (1) JP7150976B2 (ru)
KR (1) KR20200024413A (ru)
CN (1) CN112601523A (ru)
AR (1) AR116021A1 (ru)
AU (1) AU2019327262B2 (ru)
BR (1) BR112021003563A2 (ru)
CA (1) CA3107426C (ru)
EA (1) EA202190621A1 (ru)
GE (1) GEP20227388B (ru)
JO (1) JOP20190198A1 (ru)
MX (1) MX2021002277A (ru)
PH (1) PH12021550389A1 (ru)
UA (1) UA127608C2 (ru)
UY (1) UY38345A (ru)
WO (1) WO2020045940A1 (ru)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20180094A1 (ar) 2017-10-18 2019-04-18 Hk Inno N Corp مركب حلقي غير متجانس كمثبط بروتين كيناز
UY39094A (es) * 2020-02-27 2021-07-30 Hk Inno N Corp Composición farmacéutica que comprende compuesto derivado de bencimidazol
EP4271365A1 (en) * 2020-12-30 2023-11-08 HK inno.N Corporation Pharmaceutical composition comprising tegoprazan and non-steroidal anti-inflammatory drugs

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003270861A1 (en) * 2002-10-02 2004-04-23 Bristol-Myers Squibb Company Novel combination of a factor xa inhibitor and clopidogrel
US20060177504A1 (en) * 2005-02-08 2006-08-10 Renjit Sundharadas Combination pain medication
BRPI0620081B8 (pt) * 2005-12-19 2021-05-25 Pfizer composto e composição farmacêutica.
KR101784001B1 (ko) * 2006-04-04 2017-10-23 케이지 액퀴지션 엘엘씨 항혈소판제와 산 억제제를 포함하는 경구 투여용 약학 조성물
WO2010009745A1 (en) * 2008-07-25 2010-01-28 Pharmathen S.A. Solid oral dosage form containing anti-platelet agent clopidogrel and method for the preparation thereof
CA2848764A1 (en) * 2011-09-14 2013-03-21 Pozen Inc. Controlled dosing of clopidogrel with gastric acid inhibition therapies
US20140271816A1 (en) * 2013-03-15 2014-09-18 Frederick Timothy Guilford Treatment of potential platelet aggregation with liposomally formulated glutathione and clopidogrel
KR101829705B1 (ko) * 2016-09-21 2018-02-19 씨제이헬스케어 주식회사 안정성이 향상된 주사용 조성물
KR101829706B1 (ko) * 2016-09-21 2018-02-19 씨제이헬스케어 주식회사 벤즈이미다졸 유도체의 산부가염

Also Published As

Publication number Publication date
AU2019327262A1 (en) 2021-04-29
CA3107426A1 (en) 2020-03-05
EP3843722A1 (en) 2021-07-07
UY38345A (es) 2020-03-31
BR112021003563A2 (pt) 2021-05-18
AR116021A1 (es) 2021-03-25
KR20200024413A (ko) 2020-03-09
AU2019327262B2 (en) 2023-02-09
JP2022501320A (ja) 2022-01-06
UA127608C2 (uk) 2023-11-01
WO2020045940A1 (en) 2020-03-05
GEP20227388B (en) 2022-06-10
US20210251967A1 (en) 2021-08-19
CA3107426C (en) 2023-08-01
CN112601523A (zh) 2021-04-02
JOP20190198A1 (ar) 2020-02-28
PH12021550389A1 (en) 2021-09-20
EP3843722A4 (en) 2022-05-11
MX2021002277A (es) 2021-08-11
JP7150976B2 (ja) 2022-10-11

Similar Documents

Publication Publication Date Title
CY1123260T1 (el) Ενα αλας νατριου του ν-((1,2,3,5,6,7-eξaϋδpo-s-inδaken-4-υλ)καρβαμοϋλ)-1-ισοπροπυλ-1η-πυραζολο-3-σουλφοναμιδιου
PH12020551821A1 (en) Novel compounds
MX2021004431A (es) Procesos novedosos.
EA202190621A1 (ru) Фармацевтическая композиция, содержащая антитромбоцитарное средство и ингибитор секреции желудочной кислоты
EA202190960A1 (ru) Конденсированные пирролины, которые действуют как ингибиторы убиквитин-специфической протеазы 30 (usp30)
EA201890654A1 (ru) Терапевтические композиции для лечения вируса иммунодефицита человека
EA202191991A1 (ru) Новые производные гетеротрициклического соединения и их применение
EA202090688A1 (ru) Бис-амидные соединения, активирующие саркомер, и варианты их применения
PH12021551256A1 (en) Pantetheine derivatives and uses thereof
EA202090573A1 (ru) Составы нирапариба
EA202190681A1 (ru) Амиды диметиламиноазетидина в качестве jak ингибиторов
EA202090977A1 (ru) Новая комбинация активных агентов для лечения прогрессирующих фиброзирующих интерстициальных заболеваний легких (pf-ild)
EA202190586A1 (ru) N-замещенные диоксоциклобутениламино-3-гидроксипиколинамиды, приемлемые в качестве ингибиторов ccr6
MX2021003945A (es) Compuestos de indolinona para uso como inhibidores de map4k1.
EA201391018A1 (ru) Препараты иммуносупрессантов
EA201991916A1 (ru) 1,4,6-ТРИЗАМЕЩЕННЫЕ-2-АЛКИЛ-1H-БЕНЗО[d]ИМИДАЗОЛЬНЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ДИГИДРООРОТАТНЫХ ОКСИГЕНАЗНЫХ ИНГИБИТОРОВ
MX2020001531A (es) Nuevos compuestos hetorociclicos como inhibidores de cdk8/19.
PH12019500618A1 (en) Pharmaceutical composition and method for treatment of non-alcoholic fatty liver disease
EA201600486A1 (ru) Фармацевтические композиции, включающие антикоагулянт n-(5-хлорпиридин-2-ил)-2-({4-[этанимидоил(метил)амино]бензоил}амино)-5-метилбензамид
EA201991618A1 (ru) Кристаллические формы тебипенема пивоксила, композиции, содержащие их, способы изготовления и способы применения
PH12019502652A1 (en) 5,6-fused-bicyclic compounds and compositions for the treatment of parasitic diseases
EA202190064A1 (ru) Цианотриазоловые соединения и варианты их применения
EA201691058A1 (ru) Производные пирролопирролона и их применение для лечения заболеваний
EA202193007A1 (ru) Соединения пирролидина
EA201070898A1 (ru) Новое производное хиназолин-2,4-диона и лекарственные композиции на его основе для профилактики и лечения заболевания, обусловленного поражением черепно-мозгового нерва